Patents by Inventor Theodore S. Lawrence

Theodore S. Lawrence has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME
    Publication number: 20230097789
    Abstract: Provided herein are compounds that are useful in treating cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: March 30, 2023
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch, Alexander Bridges
  • EGFR DIMER DISRUPTORS AND USE OF THE SAME
    Publication number: 20220340572
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Application
    Filed: May 9, 2022
    Publication date: October 27, 2022
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • EGFR dimer disruptors and use of the same
    Patent number: 11358965
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 14, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • EGFR DIMER DISRUPTORS AND USE OF THE SAME
    Publication number: 20200377503
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Application
    Filed: February 25, 2019
    Publication date: December 3, 2020
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • Inhibitors of the Epidermal Growth Factor Receptor- Heat Shock Protein 90 Binding Interaction
    Publication number: 20150218277
    Abstract: Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 6, 2015
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence
  • Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
    Patent number: 9029502
    Abstract: Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence
  • INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR-HEAT SHOCK PROTEIN 90 BINDING INTERACTION
    Publication number: 20120190622
    Abstract: Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy.
    Type: Application
    Filed: December 19, 2011
    Publication date: July 26, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence